Search the Newsreel

Forte Biosciences Inc. (FBRX) Stock Price | Live Quotes & Charts | NASDAQ

The $2.2 Billion Reason Forte BioSciences (FBRX) Stock Is Skyrocketing Today

argenx To Acquire Forte Biosciences: What Investors Should Know (NASDAQ:ARGX)

Argenx to buy Forte Biosciences for about $2.2 billion

Belgian-Dutch immunology company argenx will acquire Forte Biosciences for approximately $2.2 billion, paying $77 per share in cash. This acquisition adds the experimental autoimmune drug FB102, a first-in-class anti-CD122 antibody, to Argenx's portfolio, which has shown early promise in treating vitiligo and celiac disease.

Argenx to Buy Forte Biosciences for $2.2 Billion

Argenx has announced an agreement to acquire Forte Biosciences for $2.2 billion, aiming to enhance its immunology drug pipeline. The European pharmaceutical company will pay $77 per share in cash for Nasdaq-listed Forte, representing a 41% premium over Forte's Friday closing price. Forte's experimental …

Forte Biosciences, Inc. Revenue Breakdown – NASDAQ:FBRX

This article focuses on the revenue breakdown of Forte Biosciences, Inc. (NASDAQ: FBRX), providing access to its financials, and market data. It highlights different sections for financial analysis, such as segments and regional performance, from sources like ICE Data Services and FactSet. The content …

Forte Biosciences (FBRX) Q1 2026 Earnings: Wider-than-Expected Loss Triggers Stock Decline - Annual Financial Report

Forte Biosciences (FBRX) Is Up 17.4% After Positive Phase 1b FB102 Vitiligo Data Release

Forte Biosciences (FBRX) shares rose 17.4% following positive Phase 1b clinical trial results for FB102 in vitiligo, demonstrating statistically significant facial repigmentation and a good safety profile. The company's investment narrative is strengthened by this data, suggesting FB102 could become a multi-indication autoimmune asset, …

Forte Biosciences stock hits 52-week high at 52.75 USD By Investing.com

Forte Biosciences (FBRX) stock reached a new 52-week high of $52.75, marking a 387.71% increase over the past year. Despite this surge, InvestingPro analysis suggests the stock is currently overvalued and in overbought territory. The company recently reported positive results from its phase 1b …

Should You Be Bullish on Forte Biosciences (FBRX)?

The Alger Small Cap Focus Fund's Q2 2026 investor letter discussed Forte Biosciences (FBRX), a clinical-stage biopharmaceutical company developing FB102 for autoimmune conditions. Despite a challenging quarter due to an equity raise and delayed vitiligo data, the fund remains constructive on FBRX, anticipating meaningful …

Forte Biosciences (FBRX) Faces Investor Scrutiny Amid Pipeline Developments - Earnings Surprise Stocks

Forte Biosciences (NASDAQ:FBRX) Upgraded at Barclays

Forte Biosciences stock trades around recent lows as cash runway and trial plans shape outlook

Forte Biosciences (FBRX) stock is trading near its recent lows, reflecting investor concerns over its limited cash reserves

Forte Biosciences (FBRX) Has a Live Clinical Setup, but the Bull Case Is Binary

Forte Biosciences (FBRX) is a clinical-stage biotech focused on its single asset, FB102, an anti-CD122 monoclonal antibody being developed for celiac disease, vitiligo, and alopecia areata. The company recently completed a significant equity raise in April 2026, bolstering its cash position ahead of crucial …

Barclays Initiates Forte Biosciences at Overweight With $74 Price Target

Barclays has initiated coverage of Forte Biosciences with an Overweight rating and a $74 price target. This indicates a positive outlook on the company's stock by the investment bank.

FBRX Initiated Coverage by Barclays -- Rating Set to Overweight

Barclays analyst Etzer Darout initiated coverage on Forte Biosciences (FBRX) with an Overweight rating and a price target of $74.00, significantly higher than its current trading price of $47.49. The positive outlook stems from the advancement of FBRX's clinical-stage product candidate, FB-102, for autoimmune …

Barclays initiates Forte Biosciences stock with overweight rating By Investing.com

Barclays has initiated coverage on Forte Biosciences Inc. (NASDAQ:FBRX) with an overweight rating and a price target of $74.00, citing potential upside for its drug FB102 in immunological disorders like celiac disease and vitiligo. The stock has surged 370% in the past year, and …

Price to sales forward of Forte Biosciences Inc. – MUN:37T

This article provides the "Price to sales forward" value for Forte Biosciences Inc. (MUN:37T) on the Munich Stock Exchange, listing it as "No trades" at the time of publication. It appears to be a data point from a financial platform, showing that no recent …

Is Forte Biosciences (FBRX) Fully Valued Following Its Positive FB102 Vitiligo Data?

Forte Biosciences (FBRX) has shown significant positive momentum with a 173.73% 1-month share price return after reporting positive Phase 1b data for FB102 in vitiligo, contributing to a 379.96% 1-year total shareholder return. Despite this, the company has no revenue and a net loss …

CapEx per share of Forte Biosciences Inc. – MUN:37T

This article provides financial data for Forte Biosciences Inc. (MUN:37T) on its CapEx per share. The content is primarily a data page from TradingView, focusing on financial metrics for the company on the Munich Stock Exchange.

Enterprise value to revenue forward of Forte Biosciences Inc. – SWB:37T

The article focuses solely on the enterprise value to revenue forward of Forte Biosciences Inc. (SWB:37T) on the Stuttgart Stock Exchange. It provides general financial information about the company but does not include any specific data points or analysis regarding its enterprise value to …

Forte Biosciences (FBRX) Stock Forecast & Analyst Ratings

This article provides a stock forecast and analyst ratings for Forte Biosciences (FBRX). It likely includes financial data, price performance, and analyst recommendations to help investors understand the company's market position and future outlook.

Millennium reports 3.2% Forte Biosciences (FBRX) stake in ownership filing

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have reported a collective beneficial ownership of 655,199 shares of Forte Biosciences, Inc. (FBRX) common stock, representing 3.2% of the total common stock. This disclosure, made via a SCHEDULE 13G/A filing, indicates shared …

Forte Biosciences stock hits 52-week high at $45.39 By Investing.com

Forte Biosciences Inc. (FBRX) stock reached a new 52-week high of $45.39, marking a significant 364.23% increase over the past year. This surge is attributed to positive investor sentiment and promising advancements, including positive results from its phase 1b study of FB102 for vitiligo. …

Should I buy Forte Biosciences (FBRX)

Forte Biosciences (NASDAQ: FBRX) posts 43% vitiligo improvement with FB102

Enovix, Forte Biosciences rally premarket; PepsiCo slips

Forte Biosciences Q1 2026 Earnings: Wider-Than-Expected Loss Amid Pre-Revenue Stage - Tax Rate Impact

Forte Biosciences (FBRX) Gains 5%: Support and Resistance Levels in Focus - Resistance Breakout Stocks

FDA fast-tracks celiac treatment as Forte Biosciences raises $172M